Low dose cabergoline induced interstitial pneumonitis.
Certain dopaminergic anti-Parkinson drugs (ergolines) have repeatedly been identified as a cause of pleuropulmonary disease with a focus on serosal cell damage. Recently, a pathogenetic link between ergolines and prior asbestos exposure was suggested, as regards the development of pleural pathology. This report describes a patient with idiopathic Parkinson's disease, who was on a multiple drug regimen including low dose cabergoline. The patient developed a febrile illness with widespread bilateral lung infiltrations nonresponsive to beta-lactam and macrolide antibiotics. Bronchoalveolar lavage and transbronchial lung biopsy showed a "hypersensitivity-like" interstitial lung disease, which cleared almost completely within 2 months after simple drug withdrawal. Circumstantial evidence suggests a so far undescribed adverse lung reaction to cabergoline, devoid of the more usual pleural changes.
Frank
W
W
Klinik III, Fachklinik für Pneumologie, Johanniterkrankenhaus Im Fläming gGmbH, Treuenbrietzen, Germany.
Moritz
R
R
Becke
B
B
Pauli
R
R
D000368:Aged; D001706:Biopsy; D001992:Bronchoalveolar Lavage Fluid / Q000166:cytology; D000077465:Cabergoline; D003937:Diagnosis, Differential; D018491:Dopamine Agonists / Q000009:adverse effects*; D004873:Ergolines / Q000009:adverse effects*; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000000981:diagnostic imaging / Q000473:pathology; D008297:Male; D010300:Parkinson Disease / Q000188:drug therapy; D013902:Radiography, Thoracic; D014057:Tomography, X-Ray Computed
D018491:Dopamine Agonists; D004873:Ergolines; D000077465:Cabergoline